Evidence map›Paper›PMID 39904549›Full record

SynthesisEuropean heart journal. Cardiovascular pharmacotherapy2025

Valve thrombosis and antithrombotic therapy after bioprosthetic mitral valve replacement: a systematic review and meta-analysis.

Mark J Zorman, Jonathan Vibhishanan, Katerina Dangas, James Castle, Ka Hou Christien Li, Marco Coronelli, Kate Eastwick-Jones, Alexander Swan, Nicky Johnson, Anurag Choksey and 15 more

Abstract readSystematic ReviewMeta-Analysis
PubMed Full text at PMC Publisher
In one paragraph

Synthesis in European heart journal. Cardiovascular pharmacotherapy, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers.

0numbers the graph read from it
0cells of the map it votes in
4citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

4 citing papers in PubMed.

  1. Article
  2. Article
  3. Article
  4. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

25 authors.

Mark J ZormanOxford Heart Centre, Oxford University Hospitals NHS Trust, Headley Way, Oxford, OX3 9DU, UK.ORCID 0000-0002-5002-1518
Jonathan VibhishananOxford Heart Centre, Oxford University Hospitals NHS Trust, Headley Way, Oxford, OX3 9DU, UK.
Katerina DangasOxford Heart Centre, Oxford University Hospitals NHS Trust, Headley Way, Oxford, OX3 9DU, UK.
James CastleOxford Heart Centre, Oxford University Hospitals NHS Trust, Headley Way, Oxford, OX3 9DU, UK.
Ka Hou Christien LiOxford Heart Centre, Oxford University Hospitals NHS Trust, Headley Way, Oxford, OX3 9DU, UK.
Marco CoronelliOxford Heart Centre, Oxford University Hospitals NHS Trust, Headley Way, Oxford, OX3 9DU, UK.
Kate Eastwick-JonesOxford Heart Centre, Oxford University Hospitals NHS Trust, Headley Way, Oxford, OX3 9DU, UK.
Alexander SwanOxford Heart Centre, Oxford University Hospitals NHS Trust, Headley Way, Oxford, OX3 9DU, UK.
Nicky JohnsonOxford Heart Centre, Oxford University Hospitals NHS Trust, Headley Way, Oxford, OX3 9DU, UK.
Anurag ChokseyOxford Heart Centre, Oxford University Hospitals NHS Trust, Headley Way, Oxford, OX3 9DU, UK.
Helen YanOxford Heart Centre, Oxford University Hospitals NHS Trust, Headley Way, Oxford, OX3 9DU, UK.
Sam G C ScottOxford Heart Centre, Oxford University Hospitals NHS Trust, Headley Way, Oxford, OX3 9DU, UK.
Matthew HenryHealth Care Libraries, University of Oxford, John Radcliffe Hospital, Headley Way, Oxford, OX3 9DU, UK.
Mark Philip CassarOxford Heart Centre, Oxford University Hospitals NHS Trust, Headley Way, Oxford, OX3 9DU, UK.
Cara BarnesOxford Heart Centre, Oxford University Hospitals NHS Trust, Headley Way, Oxford, OX3 9DU, UK.
Joao Ferreira-MartinsOxford Heart Centre, Oxford University Hospitals NHS Trust, Headley Way, Oxford, OX3 9DU, UK.
James NewtonOxford Heart Centre, Oxford University Hospitals NHS Trust, Headley Way, Oxford, OX3 9DU, UK.ORCID 0000-0002-2309-8309
Sam DawkinsOxford Heart Centre, Oxford University Hospitals NHS Trust, Headley Way, Oxford, OX3 9DU, UK.ORCID 0000-0001-9457-0570
Mohamad AlkhouliDepartment of Cardiovascular Medicine, Mayo Clinic, 200 First Street SW, Rochester, Minnesota 55905, USA.
Charanjit RihalDepartment of Cardiovascular Medicine, Mayo Clinic, 200 First Street SW, Rochester, Minnesota 55905, USA.
Mackram F EleidDepartment of Cardiovascular Medicine, Mayo Clinic, 200 First Street SW, Rochester, Minnesota 55905, USA.ORCID 0000-0001-6082-5379
Sorin V PislaruDepartment of Cardiovascular Medicine, Mayo Clinic, 200 First Street SW, Rochester, Minnesota 55905, USA.ORCID 0000-0002-5256-3150
Mayra E GuerreroDepartment of Cardiovascular Medicine, Mayo Clinic, 200 First Street SW, Rochester, Minnesota 55905, USA.
Jose Ordonez-MenaNuffield Department of Primary Care Sciences, University of Oxford, Radcliffe Observatory Quarter, Woodstock Road, OX2 6GG, UK.
Thomas J CahillOxford Heart Centre, Oxford University Hospitals NHS Trust, Headley Way, Oxford, OX3 9DU, UK.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

aimsTranscatheter mitral valve replacement (TMVR) has become a feasible alternative to surgical mitral valve replacement (SMVR) in selected patients at high surgical risk. The risk of valve thrombosis following SMVR and TMVR, and the optimal antithrombotic therapy following these procedures, remains uncertain. We aimed to compare the incidence of bioprosthetic mitral valve thrombosis (bMVT) after SMVR and TMVR, and the incidence of bMVT between patients on different antithrombotic regimens. METHODS AND

resultsA literature search of Medline, Embase, and Cochrane Library was performed between January 2000 and August 2024. Random-effects models were used to derive pooled estimates of the incidence of bMVT in the absence of prior or active endocarditis and valve thrombosis. A total of 47 studies (6170 patients, total follow-up 9541.8 patient-years) were eligible for inclusion. The overall incidence of bMVT was 5.05 [95% confidence interval (CI) 3.18-8.01, I2 = 82%] per 100-patient-years. Subclinical bMVT was more common than clinically significant bMVT: incidence 19.11 vs. 7.91 per 100-patient-years, adjusted incidence rate ratio (aIRR) 4.62 (95% CI 1.39-15.36), P = 0.012. bMVT was numerically more common after TMVR than SMVR, but the comparison was not statistically significant: incidence 7.03 vs. 0.58 per 100-patient-years, aIRR 2.19 (95% CI 0.72-6.72), P = 0.170. Patients on vitamin-K antagonists (VKA) had a lower incidence of bMVT than patients on direct oral anticoagulants (DOAC; incidence 5.72 vs. 17.08, aIRR 0.31, 95% CI 0.13-0.73, P = 0.007).

conclusionsbMVT is not uncommon, with numerically higher incidence in transcatheter compared to surgical valves, but the comparison was not statistically significant. VKAs are associated with a lower incidence of bMVT compared to DOACs.

Indexed as

BioprosthesisFibrinolytic AgentsHeart Valve ProsthesisHeart Valve Prosthesis ImplantationMitral ValveThrombosisFemaleHumansIncidenceMaleProsthesis DesignRisk AssessmentRisk FactorsTreatment OutcomeFibrinolytic AgentsSurgical mitral valve replacementTranscatheter mitral valve replacementValve thrombosis

Identifiers

PMID39904549
PMCPMC12046575

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.